Health Care Analysis on Myocardial Revascularization in Patients With Chronic Coronary Heart Disease (CHD)

Summary

Myocardial infarction and chronic coronary heart disease (cCHD) are the most frequent causes of death in Germany. Treatment options include widening of the narrowed / blocked coronary vessel via catheter and stent or bypass surgery in which the narrowed vessel sites are bridged. The "German National Disease Management Guideline on cCHD" helps doctors to decide which treatment is most appropriate for the severity of vascular damage and possible concomitant diseases of the patient. Nevertheless, there are other factors determining treatment decision. For example, the equipment or preferences of the hospital or department in which patients are admitted, play a role in the decision.

The aim of the REVASK project is to investigate whether and to what extent the collaboration of cardiology and heart surgery specialists in so-called "heart teams" influences the decision on therapy.

For this purpose, doctors and patients will be interviewed about how the treatment decision was made and how satisfied both sides are with the outcome of the treatment and the decision. In addition, claims data from several German health insurance companies (Techniker, BARMER, Betriebs- und Innungskrankenkassen) will be analyzed. Treatment data, which is documented as usual by the treating medical staff and passed on to the health insurance companies for accounting purposes, is used. Furthermore, treatment data recorded in the registers of the professional societies is analyzed.

Conditions

• Coronary Heart Disease

Sponsors & Collaborators

• University of Education Freiburg

  collaborator UNKNOWN

• Deutsche Gesellschaft für Thorax-, Herz- und Gefäßchirurgie (DGTHG)

  collaborator UNKNOWN

• Stiftung Institut fuer Herzinfarktforschung

  collaborator OTHER

• Universitätsklinikum Köln

  collaborator OTHER

• BARMER

  collaborator OTHER

• Techniker Krankenkasse

  collaborator OTHER

• InGef - Institute for Applied Health Research Berlin GmbH

  lead INDUSTRY

Principal Investigators

• Jochen Walker, Dr. med. · InGef - Institute for Applied Health Research Berlin GmbH; Spittelmarkt 12, 10117 Berlin

• Andreas Beckmann, Dr. med. · Deutsche Gesellschaft für Thorax-, Herz- und Gefäßchirurgie (DGTHG)

• Uwe Zeymer, Prof. Dr. med. · Stiftung Institut für Herzinfarktforschung (IHF)

• Peter Ihle · PMV forschungsgruppe, Universitätsklinikum Köln

• Ursula Marschall, Dr.med. · BARMER

• Ines Meier, Dr. · Techniker Krankenkasse

Eligibility

Min Age

18 Years

Max Age

105 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2021-04-01

Primary Completion

2022-12-31

Completion

2022-12-31

Countries

• Germany

Study Locations